Navigation Links
Enigma Diagnostics Announces Patent On Real-Time Monitoring of Amplification Reactions Upheld In Entirety Following Opposition From BD at European Patent Office
Date:6/16/2009

PORTON DOWN, England, June 16 /PRNewswire/ -- Enigma Diagnostics Limited, the decentralised and point-of-care molecular diagnostics company, announced today it was issued European Patent EP1044283, which covers the use of endonuclease-based reporting in PCR and other nucleic acid amplification technologies. Becton, Dickinson and Company (BD) had filed a claim in opposition to this patent which was rejected by the European Patent Office at a proceeding in Munich on May 28.

The patent is part of a substantial portfolio of intellectual property exclusively licensed to Enigma Diagnostics by the Secretary of State for Defence. The technology involves the use of a thermostable endonuclease to cut a probe that recognises a specific sequence in the target amplification product. The system may be applied to a wide variety of molecular diagnostic applications including the rapid detection of viral and bacterial pathogens.

Enigma Diagnostics has developed products that completely automate the PCR process including sample extraction, amplification and analysis for application at the point-of-care by non-laboratory operators.

John McKinley, CEO of Enigma Diagnostics, stated: "The maintenance of this key patent secures and supports the further development of Enigma's intellectual property portfolio."

    Contacts

    UK Contact:
    Enigma Diagnostics
    Deborah Cordingley
    deborah.cordingley@enigmadiagnostics.com
    +44 1980 590131

    US Contact:
    Richard Lewis Communications, Inc.
    212-827-0020
    Gregory Tiberend - Media
    gtiberend@rlcinc.com
    Cecelia Heer - Investors
    cheer@rlcinc.com

About Enigma Diagnostics Limited

Enigma Diagnostics Limited is a private UK based company specialising in developing the next generation of rapid molecular diagnostic instrument platforms for decentralised and point-of-care settings.

Enigma's innovative and proprietary technology combines the speed and sensitivity of real-time PCR (polymerase chain reaction) with the simplicity needed for field-based, decentralised and point-of-care tests providing results from a raw sample in less than 45 minutes.

The Company is targeting a number of multi-billion pound markets, core among which are the Clinical and high value Applied Markets. Enigma's commercialisation strategy is to maximise revenues from a continuous flow of market leading rapid diagnostic point-of-care and in-field instrument and assay platforms, derived from its broad Intellectual Property portfolio of issued and filed patents. Enigma will partner with market leaders where global penetration of markets is required and where appropriate will build an in-house sales and marketing capability to direct distribution of its products.

Enigma has an exclusive licence from the Defence Science and Technology Laboratory to a portfolio of patents, which represent over 15 years of UK Ministry of Defence funded research and has licences from Applied Biosystems and Celera Licences for the commercialisation of real-time PCR instruments. Enigma's R&D activities have generated a portfolio of over 50 plus worldwide patent families dedicated to real-time PCR and wider molecular technologies. Many of these patents are granted across a range of core commercial territories including US, EU and Japan with more extensive filing and grants across a number of other key territories.

For more information visit www.enigmadiagnostics.com


'/>"/>
SOURCE Enigma Diagnostics Limited
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. New light shed on the enigma of salt intake and hypertension
2. The Marketing Enigma
3. Enigma Diagnostics Announces a Signed Term Sheet for Patent Licenses with Roche Molecular Systems, Inc.
4. Quest Diagnostics to Speak at the Jefferies 3rd Annual Healthcare Conference
5. Quest Diagnostics Announces Pricing of Tender Offer for Up to $200 Million Aggregate Principal Amount of Certain of its Outstanding Notes
6. Quest Diagnostics to Speak at the William Blair & Company 29th Annual Growth Stock Conference
7. Quest Diagnostics India Recognized as Laureate by the Computerworld Honors Program
8. Quest Diagnostics Announces Early Tender Results of Offer to Purchase Up to $200 Million Aggregate Principal Amount of Certain of its Outstanding Notes
9. Quest Diagnostics HemoCue AB Subsidiary to Add Avie(TM) Hemoglobin A1c to Diabetes Point-of-Care Test Suite
10. Rules-Based Medicine, Inc. Names Tony Barnes to Lead Expanding Diagnostics Business
11. Quest Diagnostics Introduces First Comprehensive Laboratory Test To Analyze KRAS, NRAS, and BRAF Gene Mutations in Reflex Testing Service
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) of Somerset ... of specialty vendors and unique items from across the nation, this holiday-themed event will ... services offered by the VNA. The boutique will be open Saturday, November 4 ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader ... been awarded a contract by the Center for Medicare and Medicaid Services (CMS). ... the enterprise use of Agile methodologies in a consistent and high value manner ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the ... today its plans to open a flagship location in Covington, LA at 401 N. ... To Go store next to Office Depot in the Holiday Square shopping center. Its ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... delivery system that we intend to develop to enable prevention of a major ... to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... of Michigan’s 2017 Best and Brightest in Wellness® by Best and Brightest. OnSite ... program on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at the ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... -- Eli Lilly and Company (NYSE: LLY ) ... of 2017 on Tuesday, October 24, 2017. Lilly will ... the investment community and media to further detail the ... begin at 9 a.m. Eastern time. Investors, media and ... the conference call through a link that will be ...
(Date:9/28/2017)... , Sept. 28, 2017 Hill-Rom Holdings, Inc. ... earnings conference call and webcast on Friday, November 3, ... (EDT) and ending at approximately 8:30 a.m. (CDT) / ... the company,s 2017 financial performance and guidance for 2018, ... initiatives to enhance operational performance, and long-range financial outlook ...
(Date:9/25/2017)... 25, 2017   Montrium , an industry ... today—from the IQPC Trial Master Files & Inspection ... that EastHORN Clinical Services has selected eTMF ... TMF management. EastHORN, a leading European contract research ... increase transparency to enable greater collaboration with sponsors, ...
Breaking Medicine Technology: